We have identified clinical characteristics and soluble proteins (e.g. sPD-L1 and CXCL10) at the time of ALAD that are associated with long-term outcomes such as CLAD in lung transplant recipients.  We are actively validating these findings in external cohorts and performing cell-based assays to better elucidate the mechanistic links between ALAD and CLAD.

 Funding: Cystic Fibrosis Foundation (CFF004416AB322), Veterans Affairs Puget Sound Health Care System, University of Washington Department of Medicine 

 Publications: 

– The prognostic value of single and repeated ≥10% FEV1 declines for chronic lung allograft dysfunction. J Heart Lung Transplant. 2024 Dec 3:S1053 (https://pubmed.ncbi.nlm.nih.gov/39637927/)

– Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community. J Heart Lung Transplant. 2022 Jan;41(1):20-23 (https://pubmed.ncbi.nlm.nih.gov/34785136/)